Remarkable anticancer activity of triruthenium-arene clusters compared to tetraruthenium-arene clusters

被引:47
作者
Therrien, Bruno
Ang, Wee Han
Cherioux, Frederic
Vieille-Petit, Ludovic
Juillerat-Jeanneret, Lucienne
Suss-Fink, Georg
Dyson, Paul J.
机构
[1] Univ Neuchatel, Inst Chim, CH-2009 Neuchatel, Switzerland
[2] Ecole Polytech Fed Lausanne, Inst Sci & Ingn Chim, CH-1015 Lausanne, Switzerland
[3] CNRS, UMR 6174, Lab FEMTO ST, F-25044 Besancon, France
[4] Univ Inst Pathol, CHUV, CH-1011 Lausanne, Switzerland
关键词
clusters; bioorganometallic chemistry; medicinal chemistry; bioinorganic chemistry; ruthenium; in vitro assays; anticancer drugs;
D O I
10.1007/s10876-007-0140-y
中图分类号
O61 [无机化学];
学科分类号
070301 ; 081704 ;
摘要
The in vitro activity of a series of ruthenium clusters, [(eta(6)-C6H6)(eta(6)-C6Me6)(2)Ru-3(mu-H)(3)(mu(3)-O)][BF4], [(eta(6)-C6H6)(eta(6)-1,4-(PrC6H4Me)-Pr-i)(eta(6)-C6Me6)Ru-3(mu-H)(3)(mu(3)-O)][BF4], [(eta(6)-C6H6)(4)Ru-4(mu-H)(4)][BF4](2), [(eta(6)-C6H5Me)(4)Ru-4(mu-H)(4)][BF4](2) and [(eta(6)-C6H6)(4)Ru-4(mu-H)(3)(mu-OH)][Cl](2), has been evaluated against A2780 and A2780cisR ovarian carcinoma cell lines. Both triruthenium clusters are very active compared to ruthenium compounds in general, whereas the tetraruthenium clusters do not display significant cytotoxicities. Since the triruthenium clusters are known to form supramolecular interactions with arenes and other functions, it is possible that such interactions are also important with respect to their mode of biological activity. The X-ray structure analysis of [(eta(6)-C6H5Me)(4)Ru-4(mu-H)(4)][PF6](2) is also reported.
引用
收藏
页码:741 / 752
页数:12
相关论文
共 30 条
[1]   Synthesis, catalytic properties and biological activity of new water soluble ruthenium cyclopentadienyl PTA complexes [(C5R5)RuCl(PTA)2] (R = H, Me; PTA=1,3,5-triaza-7-phosphaadamantane) [J].
Akbayeva, DN ;
Gonsalvi, L ;
Oberhauser, W ;
Peruzzini, M ;
Vizza, F ;
Brüggeller, P ;
Romerosa, A ;
Sava, G ;
Bergamo, A .
CHEMICAL COMMUNICATIONS, 2003, (02) :264-265
[2]   Ruthenium antimetastatic agents [J].
Alessio, E ;
Mestroni, G ;
Bergamo, A ;
Sava, G .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (15) :1525-1535
[3]  
Alessio E, 2004, MET IONS BIOL SYST, V42, P323
[4]   Development of organometallic (organo-transition metal) pharmaceuticals [J].
Allardyce, CS ;
Dorcier, A ;
Scolaro, C ;
Dyson, PJ .
APPLIED ORGANOMETALLIC CHEMISTRY, 2005, 19 (01) :1-10
[5]   Synthesis and characterisation of some water soluble ruthenium(II)-arene complexes and an investigation of their antibiotic and antiviral properties [J].
Allardyce, CS ;
Dyson, PJ ;
Ellis, DJ ;
Salter, PA ;
Scopelliti, R .
JOURNAL OF ORGANOMETALLIC CHEMISTRY, 2003, 668 (1-2) :35-42
[6]   Classical and non-classical ruthenium-based anticancer drugs: Towards targeted chemotherapy [J].
Ang, Wee Han ;
Dyson, Paul J. .
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, 2006, (20) :4003-4018
[7]  
ANG WH, UNPUB
[8]  
[Anonymous], 2015, Acta Crystallogr., V71, P3
[9]   Control of tumour vascular permeability [J].
Baban, DF ;
Seymour, LW .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 34 (01) :109-119
[10]   ARENE RUTHENIUM(II) COMPLEXES FORMED BY DEHYDROGENATION OF CYCLOHEXADIENES WITH RUTHENIUM(III) TRICHLORIDE [J].
BENNETT, MA ;
SMITH, AK .
JOURNAL OF THE CHEMICAL SOCIETY-DALTON TRANSACTIONS, 1974, (02) :233-241